Y Intercept Hong Kong Ltd Buys 134,095 Shares of Novo Nordisk A/S $NVO

Y Intercept Hong Kong Ltd boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 420.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,981 shares of the company’s stock after acquiring an additional 134,095 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Novo Nordisk A/S were worth $6,100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. WealthCollab LLC boosted its stake in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $28,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth $29,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on NVO. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a report on Tuesday, March 10th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Five equities research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Several valuation-focused articles say Novo Nordisk may be undervalued, with DCF and market-multiple checks suggesting the stock could trade below intrinsic value. Analysts also point to Medicare GLP-1 coverage as a potential demand tailwind for Ozempic/Wegovy and the broader GLP-1 franchise. Novo Nordisk (NVO) Stock May Be 48% Undervalued On Medicare GLP 1 Coverage
• Positive Sentiment: Research highlighting the fast-growing global diabetes drug market reinforces Novo Nordisk’s long-term growth opportunity, with GLP-1 therapies still central to the company’s competitive position. Novo Nordisk (NVO) Is At The Center Of A Fast Growing Diabetes Drug Market
• Positive Sentiment: Independent valuation checks and a strong GF Score also suggest Novo Nordisk remains attractive despite recent volatility, supporting the case that the stock may have room to recover further. Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued — GF Score: 76/100

Novo Nordisk A/S Trading Down 0.1%

NVO opened at $50.39 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $71.79. The stock has a market cap of $224.97 billion, a PE ratio of 11.83, a PEG ratio of 4.60 and a beta of 0.77. The business has a 50 day moving average of $44.70 and a 200-day moving average of $45.85.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.